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Table 1
Results for Aplasia and HCT after Clofarabine Salvage
Number (%)
Patients
Number (%) Alive
(thru 10/1/12)
Patients Receiving Clofarabine 15 (100%) 6 (40%)
+Aplasia 9 (60%) 5 (33%)
+Aplasia, -AML 5 4 (27%)
+Aplasia , +AML 4 1 (7%)
-Aplasia 6 (40%) 1 (7%)
-Aplasia, -AML 2 1 (7%)
-Aplasia, +AML 4 0 (0%)
Number (%) Alive
after HCT
Patients receiving HCT 10 (67%) 6 (60%) *
+Aplasia 8 5 (50%)
+Aplasia, -AML 6 4
+Aplasia, +AML 2 1 y
-Aplasia 2 1 (10%)
-Aplasia, -AML 2
-Aplasia, +AML 0 0
* range day 100-365
y 11 months post HCT
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describe the incidence of fungal infection, VOD incidence and
relapse free survival after HCT was evaluated.
Patients/Methods: 15 patients with refractory AML received
clofarabine between January 1, 2011 and June 30, 2012.
Retrospective chart review was performed for demographic
data, disease characteristics, pathology results and outcomes
data. Speciﬁc data on fungal disease, ability to achieve
aplastic bone marrow (deﬁned as <10% cellularity approxi-
mately 14 days after treatment), subsequent treatment with
HCT and mortality data after treatment were collected.
Results: See Table 1. Clofarabinewas given alone (8 patients),
or in combination with other agents: clofarabine plus cytar-
abine (5 patients) and clofarabine, cytarabine and ﬁlgrastim
(2 patients). 2 (13%) patients developed new fungal infection
after clofarabine and there was no incidence of VOD.
Conclusion: Patients with refractory AML have a dismal
prognosis and better treatment options are needed. This
study conﬁrms prior reports that clofarabine is active in
refractory AML and can be used as a cytoreductive bridge to
HCT in aplasia. 40% of patients with refractory AML treated
with clofarabine in this study are alive (range, day 100 to
365) without evidence of disease after HCT. No increase in
fungal infections was noted after clofarabine and no post HCT
VOD observed. These results show favorable outcomes for
patients with refractory AML given clofarabine salvage with
subsequent HCT in aplasia. Future studies comparing clo-
farabine to other salvage regimens in refractory AML and
analysis of cost efﬁcacy are warranted.236
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DNA alkylating agent busulfan (Bu) and nucleoside
analogs clofarabine (Clo) and ﬂudarabine (Flu) are commonlyused as part of the pre-transplant conditioning regimen in
allogeneic hematopoietic stem cell transplantation (allo-
HSCT). We previously reported that a combination of
[Bu+Clo+Flu] has a synergistic cytotoxicity in AML cells. We
hypothesized that combination of [Bu+Clo+Flu] with histone
deacetylase inhibitor SAHA will further enhance the cyto-
toxicity. We exposed the AML cell lines KBM3/Bu2506 (KBu)
to Bu (10 mg/ml), Clo (10 nM), Flu (0.2 mM) and SAHA (0.7
mM), and OCI-AML3 to Bu (1.5 mg/ml), Clo (10 nM), Flu (0.5
mM) and SAHA (0.7 mM) alone or in various combinations.
Exposure of these cells to Bu, Clo, Flu or SAHA alone, or to
two-drug combinations [Bu+Clo], [Bu+Flu] and [Clo+Flu], did
not signiﬁcantly affect cell proliferation relative to the
control. The combination of [Bu+Clo+Flu] resulted in 20-30%
inhibition of cell proliferation. Addition of SAHA to the
[Bu+Clo+Flu] mixture further enhanced the inhibition of
proliferation of KBu and OCI-AML3 by 60% and 80%, respec-
tively, suggesting synergistic cytotoxicity. Biochemical anal-
yses suggest that this cytotoxicity may be attributed to (1)
activated DNA-damage response and cell cycle checkpoint
through ATM-CHK2-P53 pathway, (2) histone 3 and histone
4 modiﬁcations, and (3) activation of both the intrinsic and
extrinsic pathways of apoptosis. The pro-apoptotic proteins
BAX and cleaved BID increased in the mitochondria when
cells were exposed to [Bu+Clo+Flu+SAHA], and further the
pro-survival protein MCL-1 was cleaved and yielded a pro-
apoptotic 28-kDa protein, while the level of the pro-survival
protein BCL-xL decreased. Finally, phosphorylated and pan
P53 increased in themitochondria when OCI-AML3 cells that
harbor wild type P53 were exposed to [Bu+Clo+Flu] or
[Bu+Clo+Flu+SAHA]. These changes in the level of proteins
involved in mitochondrial control of apoptosis may conse-
quently cause mitochondrial outer membrane per-
meabilization (MOMP). The mitochondrial membrane
potential, as a marker for MOMP, decreased by 40% or 80%
when cells were exposed to [Bu+Clo+Flu] or [Bu+Clo+-
Flu+SAHA], respectively, and this change caused leakage of
cytochrome cand SMAC/DIABLO into the cytosol leading to
caspase activation, and release of apoptosis-inducing factor
(AIF) into the nucleus, inducing nuclear fragmentation and
cell death. These results provide a mechanistic basis for
introducing SAHA as a complement to our double nucleo-
side-busulfan combination in pre-transplant conditioning
therapy for AML patients undergoing allo-HSCT. We
hypothesize that SAHA-associated enhancement of
apoptosis will result in increased antitumor efﬁcacy with
retained safety in a clinical transplant program.237
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Background: After performing thousands of bone marrow
biopsies (BMX), our nurse lead biopsy staff started identi-
fying what is likely intuitively known about speciﬁc diseases
and their BMX characteristics. We began collecting data both
on core lengths and hemodilution rates to see if our data
validates our suspicions that patients with plasma cell
dyscrasias (PCD) have signiﬁcantly smaller core lengths and
TOTAL ALL AA AML CLL MPD HD MDS Masto PCD NHL Other
Total Bone Marrow Biopsies 3199 170 54 965 125 215 78 317 32 598 508 137
Average Core in Centimeters 1.9 1.9 1.9 1.9 1.9 1.9 2.0 1.8 2.0 1.6 2.0 1.9
Average Evaluable Core in CM. 1.3 1.4 1.4 1.3 1.4 1.3 1.6 1.3 1.5 1.1 1.6 1.3
% per Captured 41.1% 5.3% 1.7% 30.2% 3.9% 6.7% 2.4% 9.9% 1.0% 18.7% 15.9% 4.3%
% Hemodiluted per Aspirates 12.2% 9.4% 11.9% 12.3% 15.4% 17.3% 7.8% 10.2% 55.6% 9.1% 6.7% 15.7%
Drytab 19 0 0 3 2 1 1 2 1 5 3 1
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hemodilution rates.
Methods: This was a chart review from pathology reports on
3199 patients with BMX's performed at Siteman Cancer
Center between January 1st 2006 and December 30th 2011. A
convenience sample of patients having their BMX at our
center was utilized. We reviewed patients BMX results
a week following the BMX procedure to monitor job
performance of the BMX staff. Data collected included
diagnosis, gross bone marrow core length, evaluable bone
marrow core, and pathology reported bone marrow aspirate
hemodilution. For this review PCD includedMM,Monoclonal
gammopathy of undetermined signiﬁcance (MGUS), and
Amyloidosis. MPD included Chronic Myeloid Leukemia
(CML), Polycythemia Vera (PV), and Myeloﬁbrosis (MF).
Results: Our data showed that the mean bone marrow core
length among all samples was 1.9 centimeters (cm) with the
average evaluable bone marrow core length being 1.3 cm.
Mean PCD bone marrow core length was found to be much
lower at 1.6 cm with evaluable core length of 1.1 cm. Our
mean hemodiluted bone marrow aspirates rate was 12.2%.
The percent of CLL hemodiluted bone marrow aspirate was
15.4% which included 2 dry taps and MPD was 17.3% and
included 1 dry tap. Of interest, the percent of hemodiluted
samples seen in patients with Mastocytosis was 55.6%. In
reviewing our data, we noted that only 19 of 3199 patients
had a dry tap which seems quite low. It is our thought that
this is a reﬂection of the patient population we treat. Most of
the newly diagnosed AML's have their BMX in the hospital.
See chart for full data compilation.
Conclusion: In our review, it appears that plasma dyscrasias
have a bone marrow core less than the average reviewed and
CLL, MPD, and Mastocytosis have a higher hemodilution rate
in comparison. We are going to review the data further to see
if differences can be seen in older vs. younger patients.No consolidation
(N¼202)
Consolidation
(N¼402)
Outcome N Prob (95% CI) N Prob (95% CI) P-value
Grade 3-4
AGVHD
202 402
100-day 16 (12-22) 13 (10-16) .27
CGVHD 195 395
3-year 41 (34 -49) 41(36-47) .96
TRM 197 393
3-year 28 (22-35) 21 (17-25) .06
Relapse 197 393
3-year 38 (31-46) 39 (34-45) .84
DFS 197 393
3-year 34 (27-41) 41 (35-46) .15
Overall
Survival
202 402
3-year 36 (29-43)% 42 (37-47)% .15238
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Introduction: RIC allogeneic HCT is an evolving post-
remission treatment modality for medically complicated
patients with AML. Previous reports demonstrated no beneﬁt
from consolidation therapy prior tomyeloablative (MA) HCT;however, the impact of pre-HCTconsolidation therapy in RIC/
NMA HCT is largely unknown.
Methods and Patients: Using the Center for International
Bone Marrow Transplant Registry, we studied 604 adults
with AML in CR1 undergoing RIC (approximately 33% non-
myeloablative (NMA)) HCT from 2000-2010. We evaluated
outcomes based on pre-HCT exposure to consolidation
chemotherapy (no consolidation versus cytarabine based
consolidation). The impact of standard patient, disease, and
transplant variables were analyzed. Overall survival (OS),
disease free survival (DFS) relapse, and transplant related
mortality (TRM) are described.
Of the 604 patients, 402 (67%) received consolidation and
202 (33%) received none. Those who received consolidation
therapy had a higher percentage of exposure to 7+3 or
similar induction regimens (89% versus 78%, P< .01), a higher
percentage of CR1 after 1 cycle of induction (81% versus 67%
%, P < .01), a higher percentage of intermediate risk karyo-
type (48% versus 38%, P ¼ .03), and a higher proportion of
ATG or Campath exposure (42% versus 34%, P ¼ .06). Those
receiving no consolidation more frequently received Flu-
darabine + Melphalan conditioning (25% versus 13%, P ¼ .01)
and had a pre-existing MDS/MPD (34% versus 19%, P < .01).
Donor source and GVHD prophylaxis were similar between
groups.
Results: Univariate analysis revealed similar rates of
engraftment, acute and chronic graft versus host disease
(GVHD), relapse incidence, TRM, OS and DFS between groups
(Table 1). Multivariate analysis conﬁrmed the lack of impact
of pre-HCT consolidation on relapse, TRM, OS, or DFS. Higher
(> 2 grams/m2/day) versus lower dose cytarabine did not
inﬂuence results. Unfavorable karyotype was the main factor
associated with higher rates of relapse (HR 1.865, P < .0001)
and was also associated with inferior OS (HR 1.74, P < .001)
and DFS (HR 1.645, P < .0001).
Conclusion: Post transplant outcomes are not improved by
pre-HCT consolidation therapy prior to RIC conditioning.
Based on these data, donor searches for eligible patients
should begin soon after AML diagnosis to facilitate transition
to HCT upon CR1 without delay.
